Edwin Kwok

Edwin Kwok is a partner in O’Melveny’s Hong Kong office with extensive experience advising major investment banks, healthcare and TMT issuers, life science and biotech firms, Chinese state-owned enterprises, real estate and property management companies on their initial public offerings, cross-border acquisitions, public takeovers, privatizations, spin-offs, and follow-on offerings of equity and debt securities.

Edwin’s extensive experience includes advising on some of the most significant capital markets and mergers and acquisitions transactions in the Asia region.  He has advised on numerous securities offerings on the Hong Kong Stock Exchange, public takeovers and listing rules regulated notifiable transactions, some of which were highly complex involving complicated cross border implications. He is especially noted for expertise PRC real estate and property management companies’ listings on the Hong Kong Stock Exchange. He is also deeply experienced with privatizations and takeovers of Hong Kong listed companies.

Edwin has led in building and positioning O’Melveny as the market leader for life science and biotech capital markets transactions following the adoption by the Hong Kong Stock Exchange of Chapter 18A into its listing rules. Edwin led the O’Melveny team for RemeGen’s debut on the Hong Kong Stock Exchange in 2020, which was the world’s largest biopharma primary listing and IPO of 2020 and recognized as deal of the year for 2020 by China Business Law Journal. Edwin was named A-List of China’s 100 Elite Foreign Lawyers by China Business Law Journal in 2022.

ECM Transactions

• OrbusNeich Medical Group in its US$62 million IPO and listing on the Hong Kong Stock Exchange
• Sipai Health Technology Co., Ltd. in its IPO and listing on the Hong Kong Stock Exchange
• Haitong International Capital Limited and CCB International Capital Limited as joint sponsors, and other underwriters in the IPO and listing of Huafang Group Inc. on the Hong Kong Stock Exchange
• CICC and China Industrial Securities in the US$64 million top-up share placement and subscription for C&D International
• ABCI Captial Limited, CICC Hong Kong Securities Limited and other underwriters in the H-share IPO of Lushang Life Services Co., Ltd (2376.HK) on the Hong Kong Stock Exchange
• RemeGen in its approximately US$412 million A-share IPO and listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange
• Gushengtang Holdings Limited in its US$104 million IPO and listing on the Hong Kong Stock Exchange
• OrbusNeich Medical Group in its US$200 million Series A and A-2 Fundraising Rounds
• CCB International Capital Limited as sole sponsor and other underwriters in the approximately US$85 million IPO and listing of Kangqiao Service Group Limited on the Hong Kong Stock Exchange
• Brii Biosciences Limited in its US$318 million IPO and listing on the Hong Kong Stock Exchange
• BNP Paribas, China Construction Bank International, Industrial and Commercial Bank of China International and other underwriters in the spin-off and approximately US$126 million listing of Central China Management Company Limited on the Hong Kong Stock Exchange
• RemeGen Co., Ltd. in its US$515 million IPO and listing on the Hong Kong Stock Exchange
• J.P. Morgan, BofA Securities, CICC and Haitong International as joint sponsors and other underwriters in the approximately US$1.67 billion secondary listing of GDS Holdings Limited on the Hong Kong Stock Exchange
• First Shanghai Capital as sole sponsor and First Shanghai Securities as sole global coordinator, and other underwriters in the US$71 million IPO and listing of Chen Lin Education Group on the Hong Kong Stock Exchange
• Pharmaron in its approximately US$588 million dual primary listing and H share offering in Hong Kong
• Fidelity, major shareholder of Innovent Biologics, in Innovent Biologics’ US$412 million IPO on the Main Board of the Hong Kong Stock Exchange
• Viva Biotech (1873.HK) in its HK$1,521.5 million (approximately US$194 million) IPO and listing on the Hong Kong Stock Exchange
• Dexin China Holdings Company Limited (2019.HK) in its US$190 million IPO and listing on the Hong Kong Stock Exchange
• Hua Medicine (2552.HK) in its US$110 million Chapter 18A biotech company IPO sponsored by Goldman Sachs and CLSA Limited
• China Securities (International) Corporate Finance Company Limited, as the sole sponsor and lead underwriter, in the US$133 million IPO of mobile game publisher FingerTango Inc.(6860.HK) on the Hong Kong Stock Exchange
• China Securities (International) Corporate Finance Company Limited, as the sole sponsor and lead underwriter, in the US$40 million IPO of mobile game publisher Digital Hollywood Interactive Limited (2022.HK) on the Hong Kong Stock Exchange
• Bank of Tianjin in its US$948 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange
• State-owned shipping giant China Ocean Shipping (Group) Company, and China COSCO Holdings Company Limited and its associated companies in the landmark restructuring involving both China COSCO Group and China Shipping Group, comprising a series of asset acquisitions and disposals among China COSCO, China Shipping and their respective subsidiaries
• CICC, Goldman Sachs, Morgan Stanley, Citigroup, China Merchants Securities and other underwriters in the US$925 million global offering and listing of H shares of Red Star Macalline Group Corporation Ltd., the largest home improvement and furnishings shopping mall operator in China, on the Main Board of the Hong Kong Stock Exchange
• BOCOM International, ABCI, Qilu International, and other underwriters in the US$454 million global offering and listing of the H-shares of Guolian Securities Co. Ltd., one of the leading integrated securities firms in China, on the Main Board of the Hong Kong Stock Exchange
• WH Group, the world’s largest pork company with global leadership across key segments of the industry value chain, including packaged meats, fresh pork, and hog production, in its US$2.36 billion global offering and IPO
• Haitong International, J.P. Morgan, Credit Suisse, Deutsche Bank, Citigroup and UBS, and other underwriters including HSBC, Nomura, Standard Chartered, and BOCOM International, in the US$1.68 billion H share IPO of Haitong Securities Co. Ltd
• China Unicom in its US$23 billion merger with China Netcom by way of a scheme of arrangement
• BOCOM International, Morgan Stanley, Standard Chartered, BOCI Asia, CCB International, and other underwriters in the US$87 million global offering and IPO of New Century Real Estate Investment Trust, the first solely China-based hotel REIT listing in the world
• J.P. Morgan, as the sole sponsor and financial adviser, in China Daye Non-Ferrous Metals Mining Limited’s deemed new listing and reverse takeover resulting from its RMB5.8 billion acquisition of Prosper Well Group Limited
• Citigroup, UBS, and CIMB Securities Limited in the US$214 million global offering and IPO of Fu Shou Yuan International Group Limited, one of the largest providers of death care services in the PRC
• BOCOM International, Macquarie, BOCI Asia, Haitong International, ICBC International, and ABCI in the US$202 million global offering and IPO of Logan Property Holdings Company Limited
• Morgan Stanley, CITIC Securities Corporate Finance, ICBC International, and other underwriters in the US$130 million global offering and IPO of China VAST Industrial Urban Development Company Limited
• CICC and GF Securities in the US$172 million global offering and IPO of H shares of China Aluminum International Engineering Corporation Limited
• Morgan Stanley in the US$180 million global offering of Goodbaby International Holdings Limited
• CICC, Deutsche Bank AG, Hong Kong Branch, Guotai Junan Securities and CLSA Limited, as the placing agents, in the HK$4.48 billion private H share placement of Sinopec Oilfield Service Corporation (SSC) on the Main Board of the Hong Kong Stock Exchange
• Macquarie, HSBC and Nomura in the US$200 million global offering and IPO of Top Spring International Holdings, which was the first-ever listing to provide a mixed-media offering in Hong Kong
• BOCOM International, Haitong International, KGI Capital, and GF Securities in the US$78 million global offering and spin-off listing of China New City Commercial Development Limited from Zhong An Real Estate
• Goldman Sachs, Morgan Stanley, and HSBC in the spin-off and listing by introduction of Swire Properties
• Merrill Lynch and Morgan Stanley in the HK$2.56 billion spin-off and global offering of Pou Sheng International (Holdings) Limited
• Citigroup, JP Morgan, and Rothschild in the global offering and IPO of Trinity Limited
• ASMC in its HK$700 million H share global offering and IPO sponsored by Goldman Sachs and BOCI